Urban Fritsche

Urban Fritsche is a pharmaceutical analyst at Zürcher Kantonalbank, specializing in the evaluation of biotech and pharmaceutical companies. He provides insights into market dynamics and the potential impacts of drug development on stock performance. In recent news, he commented on the implications of a possible merger between AstraZeneca and Bristol Myers Squibb, highlighting that such a deal could lead to increased competition and market shifts.